Analysis · Coverage / Medicare · November 2026

Does Medicare cover Wegovy and Zepbound for weight loss?

Yes, since 1 July 2026, through a $50 demonstration that sits outside Part D and expires on 31 December 2027. The law that bans the coverage has not changed, and the permanent route has no date.

An empty marble corridor in low light, with a narrow side door standing open and a single beam of warm light falling through it onto the floor.

Does Medicare cover Wegovy and Zepbound for weight loss? Since 1 July 2026, yes, for eligible Part D enrollees, through the Medicare GLP-1 Bridge: a $50 monthly copay, central prior authorization and a fixed end date of 31 December 2027. The Part D statute that excludes weight-loss drugs has not changed.

$50Monthly copay under the Medicare GLP-1 BridgeSince 1 July 2026. Outside Part D: no deductible, no low-income subsidy, and it does not count toward true out-of-pocket costs (CMS).
2027Year the Bridge ends: 31 DecemberExtended on 21 April 2026, when CMS also delayed the Part D side of its BALANCE model for 2027 with no new date.
$245Net price per 30-day supply agreed by manufacturersReported by KFF on 11 May 2026. CMS has not published a projected cost for the Bridge.
Sources: CMS Bridge page (updated 13 Jul 2026); CMS HPMS memo (21 Apr 2026); KFF (11 May 2026).

Here is the argument of this piece. The headlines in May and July 2026 said Medicare now covers weight-loss drugs, and for a patient at the pharmacy counter that is close enough. In law it is not Part D coverage. The Medicare GLP-1 Bridge is a time-limited demonstration that runs outside the Part D benefit, with its own processor, its own copay and its own sunset. The permanent route, the Part D side of the CMS model called BALANCE, was delayed for 2027 on 21 April 2026 with no new date. Anyone who starts Wegovy, Zepbound or Foundayo through Medicare this autumn is starting a long-term drug on a programme that, as written today, stops in 14 months.

Nothing below is medical, insurance or legal advice, and this page does not tell anyone whether to take a GLP-1. It reports what CMS, the statute and published analyses say, with each document linked. The criteria quoted come from the CMS prescriber fact sheet dated June 2026, and eligibility is decided by CMS through the prescriber's prior authorization, not by any website. For the approval status of semaglutide, tirzepatide and the peptides around them, the Ozemback status tracker keeps a dated row per compound, and our piece on the orforglipron approval timeline covers the pill now sold as Foundayo.

Why didn't Medicare cover weight-loss drugs before 2026?

The Part D statute excludes them. Part D defines a covered drug in 42 U.S.C. 1395w-102(e), and paragraph (e)(2)(A) removes any drug or medical use that state Medicaid programmes may exclude under 42 U.S.C. 1396r-8(d)(2), with carve-outs for smoking cessation and a few other classes. The first item on that Medicaid list reads "agents when used for anorexia, weight loss, or weight gain". The result is that a Part D plan can cover semaglutide as Ozempic for type 2 diabetes, or Wegovy for cardiovascular risk reduction, but not the same molecule prescribed only to reduce weight. KFF's brief of 11 May 2026 describes Medicare as "prohibited by law" from covering drugs used specifically for weight loss, and nothing enacted in 2026 amended that text.

The Bridge gets around the exclusion by changing the channel, not the law. Section 402 of the Social Security Amendments of 1967 lets CMS run payment demonstrations, and the CMS memo of 21 April 2026 calls the Bridge "a time-limited Section 402 demonstration" that gives eligible Part D beneficiaries certain GLP-1 drugs "outside of the Medicare Part D benefit coverage and payment flow". Part D plans do not pay, the plan formulary is not involved, and the drug never becomes a covered Part D drug. That design explains why the copay, the paperwork and the end date look different from everything else a Medicare patient fills at the same pharmacy, and why the exclusion in the statute still stands untouched.

What is the Medicare GLP-1 Bridge and what does it cost?

The Medicare GLP-1 Bridge is a CMS demonstration that started on 1 July 2026 and, after the extension announced on 21 April 2026, runs to 31 December 2027. The CMS programme page sets a $50 copay for eligible beneficiaries and adds three conditions that matter at the counter: the Part D deductible does not apply, no low-income subsidy is provided, and "no part of the $50 copay counts towards" true out-of-pocket costs, the running total that triggers the Part D annual cap. A single central processor handles prior authorization, claims and pharmacy payment. KFF reports that manufacturers agreed a net price of $245 per 30-day supply, with CMS paying pharmacies close to list price and the manufacturer owing the difference, and that CMS has not disclosed a projected cost.

ProductUnder the BridgeSource
Wegovy injectionCoveredCMS prescriber fact sheet, June 2026
Wegovy tabletsCoveredCMS prescriber fact sheet, June 2026
Zepbound KwikPenCoveredCMS prescriber fact sheet, June 2026
Foundayo tablets (orforglipron)CoveredCMS prescriber fact sheet, June 2026
Zepbound single-dose penNot coveredCMS prescriber fact sheet, June 2026
Zepbound vialsNot coveredCMS prescriber fact sheet, June 2026
Ozempic, MounjaroNot listed; diabetes use goes through the Part D planCMS prescriber fact sheet, June 2026

The vial exclusion is the detail most coverage stories skipped. Lilly's direct cash-pay channel, which our LillyDirect analysis followed, has sold Zepbound in single-dose vials, and the CMS prescriber fact sheet states that single-dose pens and vials are not covered. A Medicare patient already paying cash for vials therefore has to change device to use the Bridge. Only 28-day or 30-day fills are covered, so there is no 90-day supply, and any switch between covered drugs, for example from Wegovy injection to Foundayo tablets, needs a new prior authorization. Foundayo is orforglipron, the Lilly pill the FDA approved for adults with obesity on 1 April 2026, which makes it the newest product on the list.

Medicare did not change the law that bans weight-loss drugs from Part D. It built a $50 side door next to it, and the side door has a closing date.

Who qualifies for Medicare coverage of Wegovy or Zepbound?

Eligibility runs through two filters. The first is the plan and the diagnosis. CMS says most people with Part D coverage can qualify, but not those in private fee-for-service plans, cost contract plans, PACE organisations and several other plan types unless they also hold a standalone drug plan. Anyone who has already received a GLP-1 through their Part D plan is out, and so is anyone with type 2 diabetes, moderate-to-severe sleep apnea or MASH, the liver disease once called NASH. For those patients CMS sends the request to the Part D plan instead. The second filter is clinical and is set by body mass index at the start of treatment, with three tiers that the fact sheet lists in full.

BMI at start of therapyAlso required
35 or moreNothing else
30 or moreHeart failure with preserved ejection fraction, uncontrolled hypertension (above 140/90 despite two medicines), or chronic kidney disease stage 3a or above
27 or morePrediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease

Two details in that table change who gets in. The BMI that counts is the one recorded "at the time my patient starts GLP-1 therapy", in the wording of the prescriber attestation, so a person who began Wegovy on cash and has since lost weight is judged on the starting figure, not on today's. And the prescriber signs the prior authorization under penalty of perjury; the CMS fact sheet warns that the programme may verify answers, such as the absence of type 2 diabetes, against Medicare data. A decision reaches the patient by mail and the prescriber within 72 hours of submission, and a denial believed to be wrong can be resubmitted. Later fills need no new authorization unless the drug changes.

What happens to Medicare GLP-1 coverage after 2027?

CMS has not published the answer. The original plan was BALANCE, the Better Approaches to Lifestyle and Nutrition for Comprehensive Health model, which was meant to bring negotiated GLP-1 prices into Part D plans from 2027 and into state Medicaid programmes from 2026. On 21 April 2026 CMS told Part D sponsors it would "delay implementation of the Medicare Part D portion" for calendar year 2027 "pending further evaluation and data collection", and told them not to indicate participation in their 2027 bids. The memo frames the extended Bridge as the source of the utilization data plans asked for, and promises only further information. As of 1 November 2026 we found no CMS notice giving a Part D start date for BALANCE.

The Medicaid half of BALANCE kept moving. The same CMS memo says states could apply until 31 July 2026 and start on a date of their choosing between 1 May 2026 and 1 January 2027, after which entry is at CMS discretion. KFF counted 13 state Medicaid programmes covering GLP-1s for obesity in January 2026, down from 16 in 2025, a decline our state-by-state coverage report tracked as it happened. For people who hold both Medicare and Medicaid, Medicare is the drug payer, so the Bridge rules apply to them too, including the line on the CMS page that no low-income subsidy is provided against the $50 copay.

Is the Bridge real coverage or only a pilot?

The strongest case against this reading is that the label matters less than the result. A beneficiary who qualifies pays $50 a month for a brand-name GLP-1, gets a decision within 72 hours, and does not have to enrol in anything separately; the pharmacy routes the claim. CMS also extended the Bridge once rather than letting it lapse after six months, and the reason it gave in April was to prepare Part D plans for BALANCE, not to wind the programme down. On that view, calling the Bridge temporary is pedantry. Switching off $50 GLP-1s for older adults who are already taking them would carry a political cost that no administration would want to pay, whatever the statute says.

The reply is that the risk sits with the patient, not with the programme. Weight regain after stopping a GLP-1 is one of the most consistent findings in this class, as our reading of the STEP-4 withdrawal trial sets out, which is why a fixed end date matters more here than in most pilots. The statute still excludes weight-loss drugs from Part D, the Part D route has no date, and the $50 does not count toward the out-of-pocket cap, so a patient who also takes expensive drugs gets no help reaching it. Anyone starting now is relying on a second extension or on BALANCE reaching Part D by January 2028, and neither has been promised in writing by CMS.

What should a Medicare patient check before using the Bridge?

The checks are administrative, not clinical. The plan has to be Part D coverage, or come with a standalone drug plan. The prescription has to name a covered product, which rules out Zepbound vials and single-dose pens, and, according to the CMS prescriber sheet, carry an E66 obesity diagnosis code with the note "SEND TO BRIDGE FOR WEIGHT MANAGEMENT"; without it the pharmacy may send the claim to the Part D plan and get a rejection. The date to keep in view is 31 December 2027. Ozemback's view is that the Bridge is real access built on a temporary legal base, and that the story of 2027 is whether CMS turns it into Part D coverage or lets the exclusion written into Part D in 2003 win by default. We will report it the day CMS publishes, and the newsletter is the fastest way to get that update.

Sources

  1. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, programme page, last updated 13 July 2026. www.cms.gov
  2. CMS, Medicare GLP-1 Bridge: information for prescribers, CMS Product No. 12235, June 2026. www.cms.gov
  3. CMS, Medicare GLP-1 Bridge: information for providers. www.cms.gov
  4. CMS, HPMS memo, Status update on the Bridge demo and BALANCE Model in Part D for CY2027, 21 April 2026. www.cms.gov
  5. KFF, What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge, 11 May 2026. www.kff.org
  6. 42 U.S.C. 1395w-102(e), Part D covered drug definition and exclusions, Cornell Legal Information Institute. www.law.cornell.edu
  7. 42 U.S.C. 1396r-8(d)(2), drugs that may be excluded or restricted, Cornell Legal Information Institute. www.law.cornell.edu
  8. Healio, FDA approves orforglipron, an oral GLP-1 for adults with obesity, 1 April 2026. www.healio.com
Cite this pageOzemback. "Does Medicare cover Wegovy and Zepbound for weight loss?." updated 1 November 2026. https://ozemback.com/blog/does-medicare-cover-wegovy-zepbound-weight-loss/

Frequently asked questions

Does Medicare cover Wegovy for weight loss in 2026?

Yes, since 1 July 2026, for eligible Part D enrollees through the Medicare GLP-1 Bridge, a CMS demonstration outside the Part D benefit. Wegovy injection and tablets, the Zepbound KwikPen and Foundayo tablets are covered for weight reduction when the BMI criteria are met and the prior authorization is approved.

How much does Wegovy or Zepbound cost with Medicare?

Under the Bridge the copay is $50 a month. The Part D deductible does not apply, no low-income subsidy is provided, and the copay does not count toward true out-of-pocket costs, according to the CMS programme page updated 13 July 2026.

Who is eligible for the Medicare GLP-1 Bridge?

Adults with Part D coverage who have not received a GLP-1 through their Part D plan and do not have type 2 diabetes, moderate-to-severe sleep apnea or MASH. At the start of therapy they need a BMI of 35 or more, 30 or more with HFpEF, uncontrolled hypertension or CKD stage 3a+, or 27 or more with prediabetes, prior heart attack, prior stroke or symptomatic peripheral artery disease.

Does Medicare cover Zepbound vials?

No. The CMS prescriber fact sheet of June 2026 states that Zepbound single-dose pens and vials are not covered under the Bridge. Only the Zepbound KwikPen is.

When does the Medicare GLP-1 Bridge end?

On 31 December 2027, after CMS extended it on 21 April 2026. The same memo delayed the Part D portion of the BALANCE model for 2027, and as of 1 November 2026 CMS had not published a Part D start date.

Does Medicare cover Ozempic?

Part D plans can cover Ozempic for type 2 diabetes under their own formularies. Ozempic and Mounjaro are not on the Bridge list, and people with type 2 diabetes are excluded from the Bridge; CMS directs those requests to the Part D plan.

Access note

The medications discussed here are prescription-only in the United States. They are legally dispensed through licensed clinicians and pharmacies, and through the telehealth platforms that hold direct supply agreements with Novo Nordisk and Eli Lilly. Ozemback is not a provider, takes no part in any clinical decision, and is not paid by any of them.

Your own numbers

Metabolic baseline

HbA1c · Fasting glucose · Fasting insulin · Lipid panel

The four numbers most often referenced in the trial literature covered on this site.

Consumer-initiated lab testing does not require a prescription in most US states. Ozemback does not interpret results, does not provide medical advice, and has no access to any reader's data. The link above is an affiliate link: if you buy a panel through it we receive a commission at no additional cost to you. We are paid for the referral, never for the result. Discuss any result with a licensed clinician.

One thoughtful letter per month.

If this essay was the kind of writing you have been missing, the monthly letter is more of it. First Sunday of every month. Free, never advice.

Subscribe to the letter
Editorial analysis, not medical advice Ozemback is an independent magazine. This essay is journalism and editorial opinion for informational purposes only and is not medical advice. The magazine does not recommend, endorse, or discourage any medication, dose, protocol, or course of treatment, and has no involvement in any clinical decision. Where we link to licensed providers, those links are clearly marked and some are affiliate links; a commission does not change what we publish. Always consult a qualified, licensed healthcare professional for any medical question or decision. See full Legal & Disclaimer.
Further reading
Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer